Insider / CYTOKINETICS INC
Hessekiel Jeffrey
Chief Legal & Admin Officer at CYTOKINETICS INC
- Company
- CYTOKINETICS INC
- Ticker
- CYTK
- First filing on record
- November 17, 2025
- Latest trade on record
- March 15, 2026
- SEC filings
- EDGAR ↗
Hessekiel Jeffrey, Chief Legal & Admin Officer at CYTOKINETICS INC, has disclosed 4 transactions in CYTK since November 17, 2025: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed March 17, 2026, 2 days after the trade.
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
In the last 12 months Hessekiel Jeffrey reported 4 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 4 | 139,088 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 3 | 0 | 0 |
| 2025 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| CYTK | Other A | March 15, 2026 | March 17, 2026 | 2d | 22,820 | — | — | derivative | Form 4 ↗ | |
| CYTK | Other A | March 15, 2026 | March 17, 2026 | 2d | 8,325 | — | — | derivative | Form 4 ↗ | |
| CYTK | Other A | March 15, 2026 | March 17, 2026 | 2d | 20,646 | — | — | Form 4 ↗ | ||
| CYTK | Other A | November 14, 2025 | November 17, 2025 | 3d | 87,297 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| March 17, 2026 | Form 4 | 0001061983-26-000022 | 3 | published | EDGAR ↗ |
| November 17, 2025 | Form 4 | 0001061983-25-000036 | 1 | published | EDGAR ↗ |
Other insiders at CYTOKINETICS INC
- Callos Andrew EVP, Chief Commercial Officer 71 rows
- Malik Fady Ibraham EVP Research & Development 70 rows
- Blum Robert I President & CEO 52 rows
- Lee Sung EVP, Chief Financial Officer 38 rows
- Kaye Edward M. MD Director 17 rows
- WIERENGA WENDELL Director 16 rows
- HENDERSON JOHN T Director 13 rows
- Daly James M Director 8 rows
- Harrington Robert Arthur Director 8 rows
- Wysenski Nancy Director 7 rows
Everyone on file, with contracts and lobbying under the company's name: CYTOKINETICS INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 4 | November 17, 2025 | March 17, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.